Quarterly Financial Results
Wanbury Receives USFDA No DMF Deficiency Letter for Multiple ANDAs
NSE
WANBURY
BSE
524212
- Wanbury Limited announced that it has received a “No DMF Deficiency Letter” from the US Food and Drug Administration (USFDA) for multiple Abbreviated New Drug Applications (ANDAs) using Wanbury’s Metformin HCl API. The company also highlighted its ongoing expansion into South Korea through an additional Drug Master File (DMF) filing.
PRICE-SENSITIVE TRIGGER
Event: Wanbury received a “No DMF Deficiency Letter” from the USFDA for multiple ANDAs.
Type: Regulatory Update
Impact: Positive
Immediate Effect:The regulatory milestone strengthens Wanbury’s compliance credentials for its Metformin HCl API supplied to multiple ANDAs and supports its expansion in regulated pharmaceutical markets.
Highlight:
- Regulatory Authority: US Food and Drug Administration (USFDA)
- Regulatory Outcome: No DMF Deficiency Letter
- Product: Metformin HCl API
- Application: Multiple ANDAs (Abbreviated New Drug Applications)
What Happened ?
Wanbury Limited informed the stock exchanges that it has received a “No DMF Deficiency Letter” from the USFDA for multiple ANDAs that use the company’s Metformin HCl Active Pharmaceutical Ingredient (API) as the source material. The company also stated that it has expanded business opportunities in South Korea by filing a Drug Master File (DMF) for another API, supporting its strategy to strengthen its presence in regulated international markets.
key details
Regulatory Highlights:
- Received a “No DMF Deficiency Letter” from the USFDA.
- The regulatory clearance covers multiple ANDAs using Wanbury’s Metformin HCl API.
- The development indicates that the USFDA has not identified deficiencies in the submitted Drug Master File for the referenced applications.
- Wanbury has also filed a DMF in South Korea for another API to expand its international business opportunities.
- The company reiterated its commitment to supplying high-quality APIs to regulated global markets.
Note:
- The filing does not disclose the number of ANDAs covered, the commercial value of the opportunity, or any expected financial impact from the regulatory development.
Risk Analysis
Summary:
- The regulatory update is positive for Wanbury’s API business, but the announcement does not quantify the commercial or financial benefits arising from the USFDA communication.
Key Risks:
- No revenue or order value has been disclosed.
- Commercial benefits depend on continued approvals and demand from ANDA customers.
- Regulatory compliance must be maintained for future supplies.
- Growth in international markets will depend on customer adoption and additional regulatory approvals.
Worst Case:
- If commercial orders linked to the approved ANDAs do not materialize or regulatory requirements change, the financial impact of the development could remain limited.
Risk Level: Low
Company Commentary
Management highlighted the following during the quarter:
- Wanbury stated that it has received a “No DMF Deficiency Letter” from the USFDA for multiple ANDAs using its Metformin HCl API.
- The company also highlighted its expansion into South Korea through the filing of another API DMF.
- Management reaffirmed its commitment to supplying high-quality APIs to new international markets for improved healthcare outcomes.
Official Exchange Filing: Wanbury Limited
